Global Tumor-Specific Antigen Market Research Report 2023

Report ID: 1875854 | Published Date: Jan 2025 | No. of Page: 91 | Base Year: 2024 | Rating: 4.4 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Report Overview
    1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global Tumor-Specific Antigen Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
        1.2.2 Coding Region
        1.2.3 Non-Coding Region
    1.3 Market by Application
        1.3.1 Global Tumor-Specific Antigen Market Share by Application: 2017 VS 2021 VS 2028
        1.3.2 Drug Discovery and Development
        1.3.3 Diagnostics
        1.3.4 Clinical and Basic Research
        1.3.5 Others
    1.4 Study Objectives
    1.5 Years Considered
2 Global Growth Trends
    2.1 Global Tumor-Specific Antigen Market Perspective (2017-2028)
    2.2 Tumor-Specific Antigen Growth Trends by Region
        2.2.1 Tumor-Specific Antigen Market Size by Region: 2017 VS 2021 VS 2028
        2.2.2 Tumor-Specific Antigen Historic Market Size by Region (2017-2022)
        2.2.3 Tumor-Specific Antigen Forecasted Market Size by Region (2023-2028)
    2.3 Tumor-Specific Antigen Market Dynamics
        2.3.1 Tumor-Specific Antigen Industry Trends
        2.3.2 Tumor-Specific Antigen Market Drivers
        2.3.3 Tumor-Specific Antigen Market Challenges
        2.3.4 Tumor-Specific Antigen Market Restraints
3 Competition Landscape by Key Players
    3.1 Global Top Tumor-Specific Antigen Players by Revenue
        3.1.1 Global Top Tumor-Specific Antigen Players by Revenue (2017-2022)
        3.1.2 Global Tumor-Specific Antigen Revenue Market Share by Players (2017-2022)
    3.2 Global Tumor-Specific Antigen Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    3.3 Players Covered: Ranking by Tumor-Specific Antigen Revenue
    3.4 Global Tumor-Specific Antigen Market Concentration Ratio
        3.4.1 Global Tumor-Specific Antigen Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Top 10 and Top 5 Companies by Tumor-Specific Antigen Revenue in 2021
    3.5 Tumor-Specific Antigen Key Players Head office and Area Served
    3.6 Key Players Tumor-Specific Antigen Product Solution and Service
    3.7 Date of Enter into Tumor-Specific Antigen Market
    3.8 Mergers & Acquisitions, Expansion Plans
4 Tumor-Specific Antigen Breakdown Data by Type
    4.1 Global Tumor-Specific Antigen Historic Market Size by Type (2017-2022)
    4.2 Global Tumor-Specific Antigen Forecasted Market Size by Type (2023-2028)
5 Tumor-Specific Antigen Breakdown Data by Application
    5.1 Global Tumor-Specific Antigen Historic Market Size by Application (2017-2022)
    5.2 Global Tumor-Specific Antigen Forecasted Market Size by Application (2023-2028)
6 North America
    6.1 North America Tumor-Specific Antigen Market Size (2017-2028)
    6.2 North America Tumor-Specific Antigen Market Size by Country (2017-2022)
    6.3 North America Tumor-Specific Antigen Market Size by Country (2023-2028)
    6.4 United States
    6.5 Canada
7 Europe
    7.1 Europe Tumor-Specific Antigen Market Size (2017-2028)
    7.2 Europe Tumor-Specific Antigen Market Size by Country (2017-2022)
    7.3 Europe Tumor-Specific Antigen Market Size by Country (2023-2028)
    7.4 Germany
    7.5 France
    7.6 U.K.
    7.7 Italy
    7.8 Russia
    7.9 Nordic Countries
8 Asia-Pacific
    8.1 Asia-Pacific Tumor-Specific Antigen Market Size (2017-2028)
    8.2 Asia-Pacific Tumor-Specific Antigen Market Size by Country (2017-2022)
    8.3 Asia-Pacific Tumor-Specific Antigen Market Size by Country (2023-2028)
    8.4 China
    8.5 Japan
    8.6 South Korea
    8.7 Southeast Asia
    8.8 India
    8.9 Australia
9 Latin America
    9.1 Latin America Tumor-Specific Antigen Market Size (2017-2028)
    9.2 Latin America Tumor-Specific Antigen Market Size by Country (2017-2022)
    9.3 Latin America Tumor-Specific Antigen Market Size by Country (2023-2028)
    9.4 Mexico
    9.5 Brazil
10 Middle East & Africa
    10.1 Middle East & Africa Tumor-Specific Antigen Market Size (2017-2028)
    10.2 Middle East & Africa Tumor-Specific Antigen Market Size by Country (2017-2022)
    10.3 Middle East & Africa Tumor-Specific Antigen Market Size by Country (2023-2028)
    10.4 Turkey
    10.5 Saudi Arabia
    10.6 UAE
11 Key Players Profiles
    11.1 Agilent Technologies
        11.1.1 Agilent Technologies Company Detail
        11.1.2 Agilent Technologies Business Overview
        11.1.3 Agilent Technologies Tumor-Specific Antigen Introduction
        11.1.4 Agilent Technologies Revenue in Tumor-Specific Antigen Business (2017-2022)
        11.1.5 Agilent Technologies Recent Development
    11.2 Creative Diagnostics
        11.2.1 Creative Diagnostics Company Detail
        11.2.2 Creative Diagnostics Business Overview
        11.2.3 Creative Diagnostics Tumor-Specific Antigen Introduction
        11.2.4 Creative Diagnostics Revenue in Tumor-Specific Antigen Business (2017-2022)
        11.2.5 Creative Diagnostics Recent Development
    11.3 Go Therapeutics
        11.3.1 Go Therapeutics Company Detail
        11.3.2 Go Therapeutics Business Overview
        11.3.3 Go Therapeutics Tumor-Specific Antigen Introduction
        11.3.4 Go Therapeutics Revenue in Tumor-Specific Antigen Business (2017-2022)
        11.3.5 Go Therapeutics Recent Development
    11.4 Lee Biosolutions
        11.4.1 Lee Biosolutions Company Detail
        11.4.2 Lee Biosolutions Business Overview
        11.4.3 Lee Biosolutions Tumor-Specific Antigen Introduction
        11.4.4 Lee Biosolutions Revenue in Tumor-Specific Antigen Business (2017-2022)
        11.4.5 Lee Biosolutions Recent Development
    11.5 Bio-Rad
        11.5.1 Bio-Rad Company Detail
        11.5.2 Bio-Rad Business Overview
        11.5.3 Bio-Rad Tumor-Specific Antigen Introduction
        11.5.4 Bio-Rad Revenue in Tumor-Specific Antigen Business (2017-2022)
        11.5.5 Bio-Rad Recent Development
    11.6 Biomrieux
        11.6.1 Biomrieux Company Detail
        11.6.2 Biomrieux Business Overview
        11.6.3 Biomrieux Tumor-Specific Antigen Introduction
        11.6.4 Biomrieux Revenue in Tumor-Specific Antigen Business (2017-2022)
        11.6.5 Biomrieux Recent Development
    11.7 Caris Life Sciences
        11.7.1 Caris Life Sciences Company Detail
        11.7.2 Caris Life Sciences Business Overview
        11.7.3 Caris Life Sciences Tumor-Specific Antigen Introduction
        11.7.4 Caris Life Sciences Revenue in Tumor-Specific Antigen Business (2017-2022)
        11.7.5 Caris Life Sciences Recent Development
    11.8 Roche
        11.8.1 Roche Company Detail
        11.8.2 Roche Business Overview
        11.8.3 Roche Tumor-Specific Antigen Introduction
        11.8.4 Roche Revenue in Tumor-Specific Antigen Business (2017-2022)
        11.8.5 Roche Recent Development
    11.9 Abcam
        11.9.1 Abcam Company Detail
        11.9.2 Abcam Business Overview
        11.9.3 Abcam Tumor-Specific Antigen Introduction
        11.9.4 Abcam Revenue in Tumor-Specific Antigen Business (2017-2022)
        11.9.5 Abcam Recent Development
    11.10 Merck Group
        11.10.1 Merck Group Company Detail
        11.10.2 Merck Group Business Overview
        11.10.3 Merck Group Tumor-Specific Antigen Introduction
        11.10.4 Merck Group Revenue in Tumor-Specific Antigen Business (2017-2022)
        11.10.5 Merck Group Recent Development
    11.11 PerkinElmer
        11.11.1 PerkinElmer Company Detail
        11.11.2 PerkinElmer Business Overview
        11.11.3 PerkinElmer Tumor-Specific Antigen Introduction
        11.11.4 PerkinElmer Revenue in Tumor-Specific Antigen Business (2017-2022)
        11.11.5 PerkinElmer Recent Development
    11.12 OriGene Technologies
        11.12.1 OriGene Technologies Company Detail
        11.12.2 OriGene Technologies Business Overview
        11.12.3 OriGene Technologies Tumor-Specific Antigen Introduction
        11.12.4 OriGene Technologies Revenue in Tumor-Specific Antigen Business (2017-2022)
        11.12.5 OriGene Technologies Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
    13.1 Research Methodology
        13.1.1 Methodology/Research Approach
        13.1.2 Data Source
    13.2 Disclaimer
    13.3 Author Details

List of Tables
    Table 1. Global Tumor-Specific Antigen Market Size Growth Rate by Type (US$ Million): 2017 VS 2021 VS 2028
    Table 2. Key Players of Coding Region
    Table 3. Key Players of Non-Coding Region
    Table 4. Global Tumor-Specific Antigen Market Size Growth by Application (US$ Million): 2017 VS 2021 VS 2028
    Table 5. Global Tumor-Specific Antigen Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
    Table 6. Global Tumor-Specific Antigen Market Size by Region (2017-2022) & (US$ Million)
    Table 7. Global Tumor-Specific Antigen Market Share by Region (2017-2022)
    Table 8. Global Tumor-Specific Antigen Forecasted Market Size by Region (2023-2028) & (US$ Million)
    Table 9. Global Tumor-Specific Antigen Market Share by Region (2023-2028)
    Table 10. Tumor-Specific Antigen Market Trends
    Table 11. Tumor-Specific Antigen Market Drivers
    Table 12. Tumor-Specific Antigen Market Challenges
    Table 13. Tumor-Specific Antigen Market Restraints
    Table 14. Global Tumor-Specific Antigen Revenue by Players (2017-2022) & (US$ Million)
    Table 15. Global Tumor-Specific Antigen Market Share by Players (2017-2022)
    Table 16. Global Top Tumor-Specific Antigen Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Tumor-Specific Antigen as of 2021)
    Table 17. Ranking of Global Top Tumor-Specific Antigen Companies by Revenue (US$ Million) in 2021
    Table 18. Global 5 Largest Players Market Share by Tumor-Specific Antigen Revenue (CR5 and HHI) & (2017-2022)
    Table 19. Key Players Headquarters and Area Served
    Table 20. Key Players Tumor-Specific Antigen Product Solution and Service
    Table 21. Date of Enter into Tumor-Specific Antigen Market
    Table 22. Mergers & Acquisitions, Expansion Plans
    Table 23. Global Tumor-Specific Antigen Market Size by Type (2017-2022) & (US$ Million)
    Table 24. Global Tumor-Specific Antigen Revenue Market Share by Type (2017-2022)
    Table 25. Global Tumor-Specific Antigen Forecasted Market Size by Type (2023-2028) & (US$ Million)
    Table 26. Global Tumor-Specific Antigen Revenue Market Share by Type (2023-2028)
    Table 27. Global Tumor-Specific Antigen Market Size by Application (2017-2022) & (US$ Million)
    Table 28. Global Tumor-Specific Antigen Revenue Market Share by Application (2017-2022)
    Table 29. Global Tumor-Specific Antigen Forecasted Market Size by Application (2023-2028) & (US$ Million)
    Table 30. Global Tumor-Specific Antigen Revenue Market Share by Application (2023-2028)
    Table 31. North America Tumor-Specific Antigen Market Size by Country (2017-2022) & (US$ Million)
    Table 32. North America Tumor-Specific Antigen Market Size by Country (2023-2028) & (US$ Million)
    Table 33. Europe Tumor-Specific Antigen Market Size by Country (2017-2022) & (US$ Million)
    Table 34. Europe Tumor-Specific Antigen Market Size by Country (2023-2028) & (US$ Million)
    Table 35. Asia-Pacific Tumor-Specific Antigen Market Size by Region (2017-2022) & (US$ Million)
    Table 36. Asia-Pacific Tumor-Specific Antigen Market Size by Region (2023-2028) & (US$ Million)
    Table 37. Latin America Tumor-Specific Antigen Market Size by Country (2017-2022) & (US$ Million)
    Table 38. Latin America Tumor-Specific Antigen Market Size by Country (2023-2028) & (US$ Million)
    Table 39. Middle East & Africa Tumor-Specific Antigen Market Size by Country (2017-2022) & (US$ Million)
    Table 40. Middle East & Africa Tumor-Specific Antigen Market Size by Country (2023-2028) & (US$ Million)
    Table 41. Agilent Technologies Company Detail
    Table 42. Agilent Technologies Business Overview
    Table 43. Agilent Technologies Tumor-Specific Antigen Product
    Table 44. Agilent Technologies Revenue in Tumor-Specific Antigen Business (2017-2022) & (US$ Million)
    Table 45. Agilent Technologies Recent Development
    Table 46. Creative Diagnostics Company Detail
    Table 47. Creative Diagnostics Business Overview
    Table 48. Creative Diagnostics Tumor-Specific Antigen Product
    Table 49. Creative Diagnostics Revenue in Tumor-Specific Antigen Business (2017-2022) & (US$ Million)
    Table 50. Creative Diagnostics Recent Development
    Table 51. Go Therapeutics Company Detail
    Table 52. Go Therapeutics Business Overview
    Table 53. Go Therapeutics Tumor-Specific Antigen Product
    Table 54. Go Therapeutics Revenue in Tumor-Specific Antigen Business (2017-2022) & (US$ Million)
    Table 55. Go Therapeutics Recent Development
    Table 56. Lee Biosolutions Company Detail
    Table 57. Lee Biosolutions Business Overview
    Table 58. Lee Biosolutions Tumor-Specific Antigen Product
    Table 59. Lee Biosolutions Revenue in Tumor-Specific Antigen Business (2017-2022) & (US$ Million)
    Table 60. Lee Biosolutions Recent Development
    Table 61. Bio-Rad Company Detail
    Table 62. Bio-Rad Business Overview
    Table 63. Bio-Rad Tumor-Specific Antigen Product
    Table 64. Bio-Rad Revenue in Tumor-Specific Antigen Business (2017-2022) & (US$ Million)
    Table 65. Bio-Rad Recent Development
    Table 66. Biomrieux Company Detail
    Table 67. Biomrieux Business Overview
    Table 68. Biomrieux Tumor-Specific Antigen Product
    Table 69. Biomrieux Revenue in Tumor-Specific Antigen Business (2017-2022) & (US$ Million)
    Table 70. Biomrieux Recent Development
    Table 71. Caris Life Sciences Company Detail
    Table 72. Caris Life Sciences Business Overview
    Table 73. Caris Life Sciences Tumor-Specific Antigen Product
    Table 74. Caris Life Sciences Revenue in Tumor-Specific Antigen Business (2017-2022) & (US$ Million)
    Table 75. Caris Life Sciences Recent Development
    Table 76. Roche Company Detail
    Table 77. Roche Business Overview
    Table 78. Roche Tumor-Specific Antigen Product
    Table 79. Roche Revenue in Tumor-Specific Antigen Business (2017-2022) & (US$ Million)
    Table 80. Roche Recent Development
    Table 81. Abcam Company Detail
    Table 82. Abcam Business Overview
    Table 83. Abcam Tumor-Specific Antigen Product
    Table 84. Abcam Revenue in Tumor-Specific Antigen Business (2017-2022) & (US$ Million)
    Table 85. Abcam Recent Development
    Table 86. Merck Group Company Detail
    Table 87. Merck Group Business Overview
    Table 88. Merck Group Tumor-Specific Antigen Product
    Table 89. Merck Group Revenue in Tumor-Specific Antigen Business (2017-2022) & (US$ Million)
    Table 90. Merck Group Recent Development
    Table 91. PerkinElmer Company Detail
    Table 92. PerkinElmer Business Overview
    Table 93. PerkinElmer Tumor-Specific AntigenProduct
    Table 94. PerkinElmer Revenue in Tumor-Specific Antigen Business (2017-2022) & (US$ Million)
    Table 95. PerkinElmer Recent Development
    Table 96. OriGene Technologies Company Detail
    Table 97. OriGene Technologies Business Overview
    Table 98. OriGene Technologies Tumor-Specific AntigenProduct
    Table 99. OriGene Technologies Revenue in Tumor-Specific Antigen Business (2017-2022) & (US$ Million)
    Table 100. OriGene Technologies Recent Development
    Table 101. Research Programs/Design for This Report
    Table 102. Key Data Information from Secondary Sources
    Table 103. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Tumor-Specific Antigen Market Share by Type: 2021 VS 2028
    Figure 2. Coding Region Features
    Figure 3. Non-Coding Region Features
    Figure 4. Global Tumor-Specific Antigen Market Share by Application in 2021 & 2028
    Figure 5. Drug Discovery and Development Case Studies
    Figure 6. Diagnostics Case Studies
    Figure 7. Clinical and Basic Research Case Studies
    Figure 8. Others Case Studies
    Figure 9. Tumor-Specific Antigen Report Years Considered
    Figure 10. Global Tumor-Specific Antigen Market Size (US$ Million), Year-over-Year: 2017-2028
    Figure 11. Global Tumor-Specific Antigen Market Size, (US$ Million), 2017 VS 2021 VS 2028
    Figure 12. Global Tumor-Specific Antigen Market Share by Region: 2021 VS 2028
    Figure 13. Global Tumor-Specific Antigen Market Share by Players in 2021
    Figure 14. Global Top Tumor-Specific Antigen Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Tumor-Specific Antigen as of 2021)
    Figure 15. The Top 10 and 5 Players Market Share by Tumor-Specific Antigen Revenue in 2021
    Figure 16. North America Tumor-Specific Antigen Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 17. North America Tumor-Specific Antigen Market Share by Country (2017-2028)
    Figure 18. United States Tumor-Specific Antigen Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 19. Canada Tumor-Specific Antigen Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 20. Europe Tumor-Specific Antigen Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 21. Europe Tumor-Specific Antigen Market Share by Country (2017-2028)
    Figure 22. Germany Tumor-Specific Antigen Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 23. France Tumor-Specific Antigen Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 24. U.K. Tumor-Specific Antigen Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 25. Italy Tumor-Specific Antigen Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 26. Russia Tumor-Specific Antigen Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 27. Nordic Countries Tumor-Specific Antigen Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 28. Asia-Pacific Tumor-Specific Antigen Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 29. Asia-Pacific Tumor-Specific Antigen Market Share by Region (2017-2028)
    Figure 30. China Tumor-Specific Antigen Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 31. Japan Tumor-Specific Antigen Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 32. South Korea Tumor-Specific Antigen Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 33. Southeast Asia Tumor-Specific Antigen Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 34. India Tumor-Specific Antigen Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 35. Australia Tumor-Specific Antigen Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 36. Latin America Tumor-Specific Antigen Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 37. Latin America Tumor-Specific Antigen Market Share by Country (2017-2028)
    Figure 38. Mexico Tumor-Specific Antigen Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 39. Brazil Tumor-Specific Antigen Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 40. Middle East & Africa Tumor-Specific Antigen Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 41. Middle East & Africa Tumor-Specific Antigen Market Share by Country (2017-2028)
    Figure 42. Turkey Tumor-Specific Antigen Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 43. Saudi Arabia Tumor-Specific Antigen Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 44. Agilent Technologies Revenue Growth Rate in Tumor-Specific Antigen Business (2017-2022)
    Figure 45. Creative Diagnostics Revenue Growth Rate in Tumor-Specific Antigen Business (2017-2022)
    Figure 46. Go Therapeutics Revenue Growth Rate in Tumor-Specific Antigen Business (2017-2022)
    Figure 47. Lee Biosolutions Revenue Growth Rate in Tumor-Specific Antigen Business (2017-2022)
    Figure 48. Bio-Rad Revenue Growth Rate in Tumor-Specific Antigen Business (2017-2022)
    Figure 49. Biomrieux Revenue Growth Rate in Tumor-Specific Antigen Business (2017-2022)
    Figure 50. Caris Life Sciences Revenue Growth Rate in Tumor-Specific Antigen Business (2017-2022)
    Figure 51. Roche Revenue Growth Rate in Tumor-Specific Antigen Business (2017-2022)
    Figure 52. Abcam Revenue Growth Rate in Tumor-Specific Antigen Business (2017-2022)
    Figure 53. Merck Group Revenue Growth Rate in Tumor-Specific Antigen Business (2017-2022)
    Figure 54. PerkinElmer Revenue Growth Rate in Tumor-Specific Antigen Business (2017-2022)
    Figure 55. OriGene Technologies Revenue Growth Rate in Tumor-Specific Antigen Business (2017-2022)
    Figure 56. Bottom-up and Top-down Approaches for This Report
    Figure 57. Data Triangulation
    Figure 58. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Agilent Technologies
Creative Diagnostics
Go Therapeutics
Lee Biosolutions
Bio-Rad
Biomrieux
Caris Life Sciences
Roche
Abcam
Merck Group
PerkinElmer
OriGene Technologies
Frequently Asked Questions
Tumor-Specific Antigen report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Tumor-Specific Antigen report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Tumor-Specific Antigen report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports

Metal Braces

The research report includes specific segments by region (country), by company, by Type and by Ap ... Read More

Tactile Imaging

The research report includes specific segments by region (country), by company, by Type and by Ap ... Read More